Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
Adagene receives $2 million from Exelixis for a preclinical milestone and becomes eligible for further milestone and royalty payments.
Rhea-AI Summary
Adagene (ADAG) achieved a preclinical milestone under its collaboration and license agreement with Exelixis, triggering a $2.0 million milestone payment related to ADC candidate XB404. XB404 uses Adagene’s SAFEbody masking technology and is designed to deliver a cytotoxic payload to ROR1/2-expressing tumors while reducing on-target, off-tumor effects.
An additional payment was also triggered by Exelixis’ selection of candidates for another SAFEbody antibody-drug conjugate program. Exelixis has rights to use the SAFEbody platform to generate masked monoclonal antibodies for ADC development, and Adagene is eligible for further development and commercialization milestones plus royalties on net sales of resulting products.
Positive
- $2.0 million preclinical milestone payment from Exelixis for XB404
- Additional undisclosed payment from Exelixis for selection of candidates in a second SAFEbody ADC program
- Eligibility for future development and commercialization milestones and royalties on net sales of SAFEbody-derived products
Negative
- None.
Key Figures
- Milestone payment
- $2.0 million
- Preclinical milestone for XB404
Previous Partnership Reports
-
ADC partnership included undisclosed upfront plus milestone and royalty payments while retaining non-ADC rights
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
antibody-drug conjugate technical
monoclonal antibodies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).
The milestone achievement is related to a preclinical milestone event for XB404 and resulted in a
Adagene is eligible to receive development and commercialization milestones and royalties on net sales of products developed.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody®, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, muzastotug (ADG126), is a masked, anti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. Muzastotug is currently in Phase 1b/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy, particularly focused on microsatellite stable (MSS) metastatic colorectal cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and X.
NEObody® is a registered trademark in the United States, China, Australia, Japan, Singapore, Switzerland, Korea, United Kingdom and the European Union. SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, including statements regarding expected clinical development plans. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the underlying drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Investor Contacts:
Raymond Tam
Raymond_tam@adagene.com
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
Media Contact:
Ian Stone
LifeSci Communications
istone@lifescicomms.com
FAQ
What triggered the $2.0 million milestone payment to Adagene?
The $2.0 million payment was triggered by the achievement of a preclinical milestone event for XB404 under Adagene’s collaboration and license agreement with Exelixis.
What is XB404 and how does Adagene’s SAFEbody technology relate to it?
XB404 is an antibody-drug conjugate candidate built with Adagene’s SAFEbody masking technology. It is designed to deliver a cytotoxic payload to ROR1/2-expressing tumors while minimizing on-target, off-tumor side effects.
What additional financial opportunities could Adagene receive from this collaboration?
Beyond the disclosed payments, Adagene is eligible to receive development and commercialization milestones, as well as royalties on net sales of products developed using its SAFEbody technology under the collaboration with Exelixis.
What rights does Exelixis have regarding Adagene’s SAFEbody platform?
Exelixis has the right to utilize Adagene’s SAFEbody technology platform to generate masked monoclonal antibodies for the development of masked antibody-drug conjugate candidates.